When piperacillin/tazobactam has been used to treat hospitalized patients with serious
infections, including nosocomial pneumonia caused by Pseudomonas aeruginosa, it has …

Study Objective. To compare the pharmacokinetic and pharmacodynamic profiles of two
dosing regimens for piperacillin‐tazobactam against commonly encountered pathogens …

Background: Although intermittent bolus dosing is currently the standard of practice for many
antimicrobial agents, beta-lactams exhibit time-dependent bacterial killing. Maximizing the …

Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous
antibiotic for moderate to severe infections used in hospital settings because of its broad …

A multiple-dose, open-labelled, randomized, two period crossover human volunteer study
was performed (i) to describe the pharmacokinetic profile and safety profile of piperacillin …

The pharmacokinetics and pharmacodynamics of two multiple-dose regimens of piperacillin-
tazobactam (3.375 g every 6 h and 4.5 g every 8 h) were evaluated at steady state for 12 …

Objective The study was to establish a population pharmacokinetic (PPK) model of
piperacillin (PIP) and tazobactam (TAZ) that explain pharmacokinetic variability and to …

The objective of this study was to evaluate the steady-state pharmacokinetics and
pharmacodynamics of piperacillin/tazobactam, administered by prolonged infusion, in …

In the present study 24 hospitalized patients requiring empirical antibiotic treatment were
randomly assigned to receive the β-lactam antibiotic/β-lactamase inhibitor combination …

Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-
lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin …